Trial
NCT05316688
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Washington
Collaborators
Blaze Bioscience Inc.
Condition
Oral Cavity Squamous Cell Carcinoma
Intervention
Near Infrared Imaging
Why stopped
Terminated due to suboptimal delineation of fluorescence between tumor and native oral cavity mucosa.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-25